Research articles (1)
Neurology Today (lww.com) How Charcot-Marie-Tooth Affects Employment Options Real-world Study Highlights Impact of CMT1A Symptoms | Charcot-Marie-Tooth News Identity-by-descent analysis […]
Continue Reading
Neurology Today (lww.com) How Charcot-Marie-Tooth Affects Employment Options Real-world Study Highlights Impact of CMT1A Symptoms | Charcot-Marie-Tooth News Identity-by-descent analysis […]
Continue Reading
Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease – BioVox
Continue ReadingNew Data from the Open-Label PLEO-CMT-FU Trial Shows SustainedBenefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type1A After 5 Years […]
Continue ReadingDr Liliane Massade – PNP22 nanoparticles are effective in treating mouse models of CMT 1A – YouTube In this presentation, […]
Continue ReadingPress Release Pharnext Announces PXT3003 for the Treatment of CharcotMarie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) […]
Continue Reading2019.08.30_PXT3003_US_FDA_EN
Continue ReadingCRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests
Continue ReadingNantes, France – May 15th, 2019 InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics […]
Continue Reading
Acceleron Pharma Inc, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics
Continue ReadingLast Updated: Saturday 24th November, 2018